title: Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
abstract: Several observations have suggested that lipoprotein (a) (Lp(a)) is a risk factor for coronary artery disease because of potential interference with fibrinolysis secondary to its activation of plasminogen. However, there are few data on the possible role of Lp(a) in liver cirrhosis. The present study was carried out, to better elucidate its relationship to the fibrinolytic system in liver cirrhosis. We studied the plasma levels of Lp(a) and the fibrinolytic parameters of 95 patients with liver cirrhosis (57 men, 38 women, aged 26-81). Patients in Child-Pugh class C (n = 32) had significantly lower levels of Lp(a) than those in class B (n = 45), and the class B had lower Lp(a) values than class A (n = 18) (1.4 (0.0-3.7) vs 2.9 (0.0-6.1) vs 3.4 (1.8-5.5); the data are log-transformed). Alpha-2-antiplasmin and plasminogen, had patterns similar to those of Lp(a), tissue plasminogen activator (t-PA) was significantly increased only in class C (class A: 7.5 +/- 5.8 ng/ml; class B: 10.8 +/- 7.7 ng/ml; class C: 19.1 +/- 11.3 ng/ml). Patients with systemic hyperfibrinolysis (cross-linked fibrin degradation products, XDP > 200 ng/ml) also had lower levels of Lp(a) than those without 1.6 (0.0-4.4) vs (0.0-6.1); p = 0.0002. There was a significant correlation between Lp(a) and plasminogen (r = 0.43; p = 0.001). Lipoprotein (a) progressively decreases as liver cirrhosis worsens but it appears unlikely to be involved in causing the hyperfibrinolytic state often observed in advanced liver cirrhosis, in which there are marked abnormalities of several other fibrinolytic parameters, also including increased t-PA and decreased inhibitors.
authors.affiliation: Department of Internal Medicine, San Carlo Borromeo General Hospital, Milan, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Cimminiello
authors.forename: M
authors.initials: M
authors.lastname: Soncini
authors.forename: M C
authors.initials: MC
authors.lastname: Gerosa
authors.forename: V
authors.initials: V
authors.lastname: Toschi
authors.forename: A
authors.initials: A
authors.lastname: Motta
authors.forename: G
authors.initials: G
authors.lastname: Bonfardeci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000097:blood; D005260:Female; D005343:Fibrinolytic Agents / Q000097:blood*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood* / Q000145:classification; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D017270:Lipoprotein(a); D010958:Plasminogen; D010959:Tissue Plasminogen Activator